Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24866428 | 0.89 | AKT2 (0.44) | AKT2NOS2NAMPTKCNH2HRH2 | |
| SCHEMBL23732868 | 0.83 | — | — | |
| SCHEMBL26999527 | 0.80 | PTGS2 (0.47) | LMNA | |
| SCHEMBL2541661 | 0.80 | PTGS2 (0.47) | LMNA | |
| SCHEMBL10948171 | 0.80 | PTGS2 (0.47) | LMNA | |
| SCHEMBL20539012 | 0.80 | PTGS2 (0.47) | LMNA | |
| SCHEMBL21263656 | 0.78 | NOS2 (0.44) | AKT2NOS2KCNH2LMNAAPEX1 | |
| SCHEMBL458851 | 0.78 | TDP1 (0.44) | AKT2NOS2LMNA | |
| SCHEMBL5067336 | 0.78 | AKT2 (0.56) | AKT2 | |
| SCHEMBL836016 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185302-B1 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | GENENCOR INT (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-1185302-B1 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | GENENCOR INT (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8431121-B2 | Specifically targeted catalytic antagonists and uses thereof | DANISCO US INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110262419-A1 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | DANISCO US, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20040170618-A1 | antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. | DAVIS BENJAMIN G (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1185302-A2 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | GENENCOR INTERNATIONAL, INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000064485-A9 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | GENENCOR INT (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2000064485-A2 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | GENENCOR INTERNATIONAL, INC. (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262419-A1 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | ENGASE, GAA, DNPEP | AKT2 2536/4885NOS2 4728/4885NAMPT 1715/4885 |
| US-20040170618-A1 | antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. | ENGASE, GPR84, ADGRF1 | AKT2 4142/4885NOS2 4724/4885NAMPT 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.